This document provides an overview of regulations for combination products and medical devices in the United States and India. It discusses what combination products are, examples of combination products, and the roles of the US FDA Office of Combination Products in classifying and assigning combination products for review. It also summarizes the regulatory requirements for medical devices in the US, including establishment registration, medical device listing, premarket notification, premarket approval, and quality system regulations. The latest developments in medical device regulation in India are also briefly outlined.
Investigational medical product dossierSachinFartade
Investigational medical product dossier is document made to apply for clinical trial application in European Union. European Medical Agency is regulatory body for drug approval in European Union.
Investigational medical product dossierSachinFartade
Investigational medical product dossier is document made to apply for clinical trial application in European Union. European Medical Agency is regulatory body for drug approval in European Union.
M.pharm (Pharmaceutics) modern pharmacy unit-5 Study of consolidation parameters; Diffusion parameters, Dissolution
parameters and Pharmacokinetic parameters, Heckel plots, Similarity factors – f2
and f1, Higuchi and Peppas plot, Linearity Concept of significance, Standard
deviation , Chi square test, students T-test , ANOVA test
Objectives , policies and principles of cGMP guidelines in pharmaceutical ind...JaskiranKaur72
The presentation contains detailed information about the current GMP in the pharmaceutical industry. It has objectives , policies and principles of cGMP guidelines.
Pdf file is being attached in the link below- https://drive.google.com/file/d/11al8n8AqrkUR_Vnm-z4Mp6O0elzyniEz/view?usp=drivesdk
overview of Japan pharmaceutical regulatory authority - PMDANandhanan
PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare.
Its obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices.
It conduct scientific reviews of marketing authorization application of pharmaceuticals and medical devices, monitoring of their post-marketing safety and also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare.
Its obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices.
It conduct scientific reviews of marketing authorization application of pharmaceuticals and medical devices, monitoring of their post-marketing safety and also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.
M.pharm (Pharmaceutics) modern pharmacy unit-5 Study of consolidation parameters; Diffusion parameters, Dissolution
parameters and Pharmacokinetic parameters, Heckel plots, Similarity factors – f2
and f1, Higuchi and Peppas plot, Linearity Concept of significance, Standard
deviation , Chi square test, students T-test , ANOVA test
Objectives , policies and principles of cGMP guidelines in pharmaceutical ind...JaskiranKaur72
The presentation contains detailed information about the current GMP in the pharmaceutical industry. It has objectives , policies and principles of cGMP guidelines.
Pdf file is being attached in the link below- https://drive.google.com/file/d/11al8n8AqrkUR_Vnm-z4Mp6O0elzyniEz/view?usp=drivesdk
overview of Japan pharmaceutical regulatory authority - PMDANandhanan
PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare.
Its obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices.
It conduct scientific reviews of marketing authorization application of pharmaceuticals and medical devices, monitoring of their post-marketing safety and also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.PMDA (Pharmaceuticals and Medical Devices Agency) is Japanese regulatory agency, working together with Ministry of Health, Labour and Welfare.
Its obligation is to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices.
It conduct scientific reviews of marketing authorization application of pharmaceuticals and medical devices, monitoring of their post-marketing safety and also responsible for providing relief compensation for sufferers from adverse drug reaction and infections by pharmaceuticals or biological products.
Clinical research : Drug regulatory affairs and Pharmacovigilance.ProfDnyaneshwariJosh
Schedule Y, FDA, Appendices, Post marketing surveillance,Clinical trial,WHO,ICH-GCP, FDA-CFR, Safety,Adverse Drug reaction, Adverse Event(AE), Serious Adverse Event(SAE),Reporting, IND , 3500A form
Full description of the regulatory process for the medical devices registration in South Korea. It contains information about: classification, substantial equivalence, product license, testing, Korean Good Manufacturing Practice (KGMP)...
Find more on: http://kobridgeconsulting.com/?p=767
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptxFaizanShaikh204666
the presentation give idea about what is medical devices?
definition's given by cdsco and usfda
what is clinical investigation in evaluation in medical devices?
Federal Regulatory Issues Us Food And Drug Administration Medical Device Amen...Jacobe2008
Authors:
Harvard-MIT Division of Health Sciences and Technology HST.535: Principles and Practice of Tissue Engineering Instructors: Myron Spector
Massachusetts Institute of Technology
Harvard Medical School Brigham and Women's Hospital VA Boston Healthcare
Japan drug and cosmetics regulation.pdfBhavikaAPatel
Japan drug and cosmetics regulation
information about
organisation of PMDA
Function of PMDA
IND and NDA application
Classification of drug product
Types of Application
DMF system in Japan
Post marketing surveillance
Importing cosmetics in Japan
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
REGULATIONS FOR COMBINATION PRODUCTS AND MEDICAL DEVICES
1. REGULATIONS FOR COMBINATION PRODUCTS
AND MEDICAL DEVICES
PRESENTED BY :
ARUN PANDIYAN.E
FIRST YEAR
DEPARTMENT OF PHARMACEUTICS
SRIHER, PORUR.
1
2. COMBINATION PRODUCT :
A combination product is a product composed of any combination of a drug and a device: a
biological product and a device: a drug and a biological product: or a drug, device, and a
biological product.
Example: -
Monoclonal antibody combined with a therapeutic drug
Device coated or impregnated with a drug or biologic
Pacing lead with steroid-coated tip, catheter with antimicrobial coating, condom with spermicide,
transdermal patch
Prefilled drug delivery systems (syringes, insulin injector pen, metered dose inhaler)
2
5. MEDICAL DEVICES :
A medical device is an instrument, apparatus, in vitro reagent , implant or other similar or related
article, which is intended for use in the diagnosis of disease or other condition ,or in the cure ,
mitigation , treatment , or prevention of disease or intended to affect the structure or any function of
the body and which does not achieve any of its primary intended purposes through its chemical
action within or on the body.
In US, FDA has 3 assigned centers for regulation:
1. Center for Drug Evaluation and Research (CDER) (for combination product)
2. Center for Devices and Radiological Health (CDRH) (for Devices)
3. Center for Biologics Evaluation and Research (CBER)
Example: Wound dressing with antimicrobial — typically a device (CDRH)
Asthma inhaler or medicinal patch — typical a drug (CDER)
5
10. ARTICLES DECLARED NOT TO BE MEDICAL DEVICES :
Therapeutic Goods (Articles that are not Medical Devices) Order No. 1 of 2010 declares that the
following are not medical devices:
1. Chemical oxygen generators
2. In-vivo imaging agents
3. Product intended to deliver a medicine, where the medicine and device
are a single integral product (which is not reusable)
4. Products incorporating tissues, cells, substances of human origin
5. Products incorporating viable tissues, cells, substances of animal origin
6. Hospital and household grade disinfectants
10
11. SOFTWARE – IS IT A MEDICAL DEVICE?
A software product is a medical device if it meets the definition of a medical device
(s41BD of the Therapeutic Goods Act 1989).
Examples
• Mobile app used to measure blood glucose levels for monitoring diabetes.
• Software which analyses and interprets ECG signals.
• Software running an infusion pump to control dose delivery.
11
13. OFFICE OF COMBINATION PRODUCTS (OCP) :
The Office of Combination Products was established on December 24, 2002 as required by
Sec. 204 of the Medical Device User Fee and Modernization Act of 2002 (MDUFMA).
Its duties are detailed in section 503(g) of the Federal Food, Drug, and Cosmetic Act (21
USC 353(g))
THE ROLES OF THE OFFICE OF COMBINATION PRODUCTS (OCP) INCLUDE:
To serve as a focal point for combination product issues and for medical product
classification and assignment issues for agency staff and industry.
To develop guidance and regulations to clarify the regulation of combination products.
13
14. To classify medical products as drugs, devices, biological products or combination products and
assign them to an FDA center for premarket review and regulation, where their classification or
assignment is unclear or in dispute.
To ensure timely and effective premarket review of combination products by overseeing the
timeliness, alignment of coordination of reviews involving more than one agency center, including
through monitoring and management of the intercenter consult process.
To ensure consistent and appropriate postmarket regulation of combination products.
To resolve disputes regarding the timeliness of premarket review of combination products.
14
15. WHO WORKS IN THE OFFICE OF COMBINATION PRODUCTS?
Office of Combination Products staff members:
Thinh X. Nguyen - Director
Patricia Y. Love, MD., MBA. - Deputy Director
John (Barr) Weiner, J.D. - Associate Director for Policy and Product Classification Officer
Leigh Hayes, J.D. – Lead Product Jurisdiction Officer
Joseph Milone, Ph.D. - Senior Scientific Reviewer
Jose L. Moreno, Ph.D. - Senior Scientific Reviewer
Diana M. Yoon, Ph.D. - Senior Scientific Reviewer
Melissa Burns - Senior Program Manager
Bindi Nikhar, MD. - Associate Clinical Director
Maryam Mokhtarzadeh, MD. – Senior Medical Officer
Bibi K. Jakrali - Management Analyst
Danita M. Dixon - Project Management Officer
15
16. HOW ARE COMBINATION PRODUCTS ASSIGNED FOR REVIEW?
Combination products are assigned to a FDA center that will have primary jurisdiction for its premarket
review and regulation.
Determination of the “primary mode of action” (PMOA) of the combination product. (provides the most
important therapeutic action of the combination product)
In some cases, the most important therapeutic action cannot be determined. For example, a combination
product may have two independent modes of action, neither of which is subordinate to the other.
FDA’s regulations at 21 CFR Part 3 include an algorithm for determining center assignment.
16
17. DEVICE REGULATION :
FDA's Center for Devices and Radiological Health (CDRH) is responsible for regulating firms
who manufacture, repackage, relabel, and/or import medical devices sold in the United States.
FDA has established classifications for approximately 1,700 different generic types of devices and
grouped them into 16 medical specialties referred to as panels.
Each of these generic types of devices is assigned to one of three regulatory classes based on the
level of control necessary to assure the safety and effectiveness of the device.
1. Class I devices are exempt from Premarket Notification (lowest risk)
2. Class II devices require Premarket Notification (moderate risk)
3. Class III devices require Premarket Approval. (high risk)
17
18. REGULATION IN INDIA :
In India medical devices are governed by CDSCO (Central Drugs Standard Control
Organization) which is regulated by Directorate General of Health Services , Ministry of Health
and Family Welfare , Government of India.
CDSCO is the only government body which regulate the
medical devices.
Many committees had been set up and given their opinion and recommendation , like the
Mahelkar Committee – Central Drug Standard Control Organization.
All these are now being taken into to form the Indian Medical Device regulatory Act
(IMRDA).
18
19. IMRDA:
Indian Medical Devices Regulatory Act come in force December 31, 2009.
Inputs to be sent to Dr. B Hari Gopal , Adviser Department Technology, New Delhi.
The composition of the committee is represented by:
1.Central Government
2.Eminent Jurist
3.Two eminent medical practitioners
4.Two eminent medical technologists
5.Secretary General Quality council
19
20. IMRDA - ESSENTIAL PRINCIPLES :
1. Should not compromise health and safety.
2. Design and manufacture of devices must conform with safety principles.
3. Long term safety should be ensured.
4. Benefits of the devices must outweigh any side effects.
5. Medical devices should be useful for the intended purpose.
20
21. IMRDA - THE REGULATION
Will issue :
1. Design and manufacturing requirements.
2. Performance evaluation.
3. Demonstration of device standards , testing and compliance.
4. Regulation of post marketing follow up.
5. Regulation of recalls.
6. Legislate and punishment for non compliance.
7. Principle of safety.
21
22. REGULATORY REQUIRMENTS OF MEDICAL DEVICE
DISTRIBUTION IN US:
The basic regulatory requirements that manufacturers of medical devices distributed in the U.S. must comply
with are:
1. Establishment Registration:
Manufacturer/Importers must register their establishment with FDA.
Information verified annually between 1st Oct-31st Dec
2. Medical Device listing:
Manufacturers must list their devices with the FDA with information about manufacturer, distributer,
specification, accessories/component, remanufacturer, US manufacturer of 'export only' devices.
3. Premarket notification:
Letter of substantial equivalence from FDA required before commercial distribution.
4. Premarket approval (PMA):
Class III devices are high risk devices so that include the submission of clinical data to support claims
made for the device.
22
23. 5. Investigational device Exemption (IDE) :
Allows the investigational device to be used in a clinical study in order to collect safety and
effectiveness data required to support a Premarket.
Clinical studies with devices of significant risk must be approved by FDA and by an Institutional
Review Board (IRB) before the study can begin
6. Quality system regulation (QC)/ Good Manufacturing Practice (GMP):
Includes methods, facilities and controls used for: designing, purchasing, manufacturing, packaging,
labeling, storing, installing and servicing of medical / devices to assure compliance.
7. Labeling:
Includes labels on the device as well as descriptive and informational literature that accompanies the
device.
8. Medical Device Reporting (post marketing):
To detect and correct problems in a timely manner and to identify and monitor significant adverse
events involving medical devices.
23
24. For pre-market and post-market regulation of combination product and medical device, regulatory
investigational application should include all information on the entire combination product and
device including the details on the drug and devil that typically would be submitted in an IND.
The US FDA Office of Combination Products (OCP) is a statutorily mandate office for regulatory
affairs in combination product.
The role of the OCP is as follows:
1. Classifies and assigns therapeutic products
2.Coordinates and oversees regulation of combination products
3. Facilitate meetings between sponsors and review staff
4. Help resolve product class and product specific combination product concerns
5. Help resolve disputes between Centers or with sponsors
24
25. US FDA uses three key concepts in the regulation of combination products:
1. Constituent parts retain regulatory status and duties
2. Combination products are a distinct regulatory class
3. Comprehensive, effective oversight without undue redundancy
The Conformity Assessment is done by the US FDA Centers :
1. Based on Safety and Effectiveness—constituent parts & interaction of constituent parts
2. Combined/coordinated analysis and decision-making by Centers, with OCP input as needed
3. Varying pathways to market depending on technology and PMOA (primary modes of action,
assigned lead center)
4. Consistent procedure and standards to review process.
25
26. LATEST DEVELOPMENT IN MEDICAL DEVICE REGULATION
There are only14 medical devices regulated by Drug Controller General of India (DCGI).
Currently, a number of specific medical devices are regulated as drugs and fall under India’s Drugs and
Cosmetics Act (DCA).
Since 2008, both the Indian Department of Science and Technology and the Ministry of Health have
sought to completely restructure the regulations for medical devices.
Department of Science and Technology : proposed creation of a Medical Devices Regulatory Authority
that would operate similar to a division within the CDSCO (Central Drugs Standard Control
Organization) .
Ministry of Health: proposed revision of the DCA that would create a Central Drug Authority to function
similarly to the U.S. FDA.
26
27. The CDSCO is continuing to entrench its own medical device regulation standards. In June 2009, it
seemed as if the CDSCO would begin its own form of medical device regulations.
CDSCO: released schedule M-3 which provided an official definition for medical devices, outlined a four
level medical device risk classification scheme, created a body within the CDSCO to regulate medical
devices in India.
Ministry of Health and Family Welfare, Government of India, with WHO funding, initiated a country
wide National Pharmacovigilance Program.
Central Drugs Standard Control Organization (CDSCO), New Delhi, coordinates the program. The
Honorable Minister of Health, Dr. Anbumani Ramadass at New Delhi, officially launched the program on
November 23, 2004.
27